Search

Displaying results 791 - 800 of 10000 in total
  1. Drug

    Iron Dextran

    go.drugbank.com/drugs/DB00893
    ApprovedInvestigationalVet approved

    Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. … Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use.

    Categories: Compounds used in a research, industrial, or household settingProducts: Cosmofer 50mg/ml Solution for injection and for infusion, FERRO 2000 SOLUTION FOR INJECTION
  2. Drug

    Necitumumab

    go.drugbank.com/drugs/DB09559
    ApprovedInvestigationalWithdrawn

    Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist.

    Products: PORTRAZZA CONCENTRATE FOR SOLUTION FOR INFUSION 800MG/50ML
  3. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk … for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012.

    Categories: Drugs for Treatment of Bone DiseasesProducts: XGEVA 120mg Solution for Injection, XGEVA Solution for Injection 120 mg/vial
  4. Drug

    Aluminum chlorohydrate

    go.drugbank.com/drugs/DB11573
    Approved

    It is included up to 25% in over-the-counter hygiene products as an active antiperspirant agent. … It is also used as a coagulant in the water purification process.

    Mixtures: Watkins Roll On Deodorant, Anti-perspirant Roll-ON DeodCategories: Drugs for Treatment of Bone Diseases
  5. Drug

    Biperiden

    go.drugbank.com/drugs/DB00810
    ApprovedInvestigationalWithdrawn

    It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. … A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism.

    Synonyms: 1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol, alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanolProducts: AKINETON 5 MG/ML IM/IV ENJEKSIYON ICIN ÇÖZELTİ ICEREN AMPUL, 10 ADET, AKINETON 5 MG/ML IM/IV ENJEKSIYON ICIN ÇÖZELTİ ICEREN AMPUL, 5 ADET
  6. Drug

    Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15681
    ApprovedInvestigational

    Products: NeisVac-C Injektionssuspension in einer Fertigspritze
  7. Drug

    Pancrelipase

    go.drugbank.com/drugs/DB00085
    ApprovedInvestigational

    [L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147]. … [L2509] The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.

    Mixtures: Neo Life Enzyme TabInternational brands: Ku-Zyme
  8. Drug

    Iothalamic acid

    go.drugbank.com/drugs/DB09133
    Approved

    Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.

    Salts: Iothalamate sodium I-125Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast Activity
  9. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848] … [L42245] In June 2022, the European Medicines Agency approved mosunetuzumab for the treatment of adult patients with relapsed or refractory (R/R) FL who have received at least two prior systemic therapies

    Products: Lunsumio 1mg/ml Concentrate for Solution for Infusion
  10. Drug

    Natalizumab

    go.drugbank.com/drugs/DB00108
    ApprovedInvestigational

    In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. … [L48041] While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy

    Products: Tysabri Concentrate for Solution for Infusion 300mg/15ml